You are Leaving Medically
By following this link, you are leaving Roche Website and entering a site that is not owned or controlled by Roche. Roche does not take any responsibility for acces to or use of this website, nor for any content therein.
You are Leaving the Global Medically Site
By following this link, you are being redirected to another Roche page.
The patient impact of 11 years of ocrelizumab treatment in multiple sclerosis: long-term data from the Phase III OPERA and ORATORIO studies
Early and sustained treatment of patients with MS with a high efficacy therapy delays disability progression and the time to reaching key long-term disability milestones. OCR has a robust long-term safety and efficacy experience across the MS spectrum. Results for OCR over eleven years are reported for 48-week CDP and other measures of progression (including the rate of repeated 48-week CDP, and the time to requiring walking aid or wheelchair) during OPERA I/II (NCT01247324/NCT01412333), ORATORIO (NCT01194570) and their open-label extensions.
Request medical material
Would you like to receive this poster via email to view later?